<!DOCTYPE html>
        <html lang="en">
        <head>
          <meta charset="UTF-8" />
          <meta name="viewport" content="width=device-width, initial-scale=1.0" />
          <title>MinMaxMuscle | Tesamorelin</title>
          <meta name="description" content="Curated source summaries for Tesamorelin." />
          <link rel="stylesheet" href="../assets/css/style.css" />
        </head>
        <body>
          <header>
            <div class="nav-container">
              <div class="logo">
                <img src="../assets/img/logo.png" alt="MinMaxMuscle Logo" />
                <span>MINMAXMUSCLE</span>
              </div>
              <nav class="desktop-nav">
                <a href="../index.html">Home</a>
                <a href="../training.html">Training</a>
                <a href="../nutrition.html">Nutrition</a>
                <a href="../peptides.html">Peptides</a>
                <a href="../coaching.html">Coaching</a>
                <a href="../contact.html">Contact</a>
              </nav>
              <div class="hamburger" id="hamburger">
                <span></span>
                <span></span>
                <span></span>
              </div>
            </div>
            <div class="mobile-menu" id="mobileMenu">
              <a href="../index.html">Home</a>
              <a href="../training.html">Training</a>
              <a href="../nutrition.html">Nutrition</a>
              <a href="../peptides.html">Peptides</a>
              <a href="../coaching.html">Coaching</a>
              <a href="../contact.html">Contact</a>
            </div>
          </header>
          <main>
            <section class="hero">
              <h1>Tesamorelin</h1>
              <p>Automated source summaries for educational review. Verify claims with qualified professionals.</p>
            </section>
            <section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://en.wikipedia.org/wiki/Tesamorelin" rel="noopener noreferrer" target="_blank">https://en.wikipedia.org/wiki/Tesamorelin</a></p>
  <ul>
    <li>Main page</li><li>Contents</li><li>Current events</li><li>Random article</li><li>About Wikipedia</li><li>Contact us</li><li>Help</li><li>Learn to edit</li><li>Community portal</li><li>Recent changes</li><li>Upload file</li><li>Special pages</li><li>Donate</li><li>Create account</li><li>Log in</li><li># Contents</li><li>(Top)</li><li>1 Mechanism of action</li><li>2 Contraindication</li><li>3 Adverse effects</li><li>4 See also</li><li>5 References</li><li># Tesamorelin</li><li>العربية</li><li>Español</li><li>Français</li><li>Italiano</li><li>Kiswahili</li><li>ଓଡ଼ିଆ</li><li>Português</li><li>Српски / srpski</li><li>Srpskohrvatski / српскохрватски</li><li>తెలుగు</li><li>Türkçe</li><li>Tiếng Việt</li><li>Article</li><li>Talk</li><li>Read</li><li>Edit</li><li>View history</li><li>What links here</li><li>Related changes</li><li>Permanent link</li><li>Page information</li><li>Cite this page</li><li>Get shortened URL</li><li>Download QR code</li><li>Download as PDF</li><li>Printable version</li><li>Wikidata item</li><li>H01AC06 ( WHO )</li><li>US : ℞-only</li><li>In general: ℞ (Prescription only)</li><li>218949-48-5 Y</li><li>as salt: 901758-09-6 Y</li><li>16137828</li><li>34982925</li><li>MQG94M5EEO</li><li>as salt: LGW5H38VE3 Y</li><li>D09015 Y</li><li>CHEBI:63626</li><li>DTXSID00583207</li><li>Interactive image</li><li>CCC[C@@H](C(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(cc1)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](Cc3ccc(cc3)O)NC(=O)C/C=C/CC</li><li>InChI=1S/C220H364N72O67S/c1-24-28-30-54-162(307)259-144(92-119-55-59-121(298)60-56-119)197(342)254-115(20)178(323)275-149(96-168(315)316)198(343)255-116(21)179(324)290-171(110(15)26-3)213(358)283-146(91-118-44-31-29-32-45-118)205(350)292-173(117(22)297)214(359)284-148(95-161(229)306)204(349)288-154(104-296)209(354)279-145(93-120-57-61-122(299)62-58-120)202(347)267-130(52-41-84-247-219(239)240)186(331)266-126(47-34-36-79-222)196(341)289-170(109(13)14)211(356)282-140(87-105(5)6)182(327)251-100-165(310)257-133(64-71-156(224)301)189(334)277-143(90-108(11)12)201(346)287-151(101-293)207(352)256-114(19)177(322)263-129(51-40-83-246-218(237)238)185(330)265-125(46-33-35-78-221)188(333)276-142(89-107(9)10)200(345)278-141(88-106(7)8)199(344)272-137(67-74-159(227)304)194(339)281-150(97-169(317)318)206(351)291-172(111(16)27-4)212(357)274-139(77-86-360-23)195(340)286-152(102-294)208(353)268-131(53-42-85-248-220(241)242)187(332)270-135(65-72-157(225)302)191(336)269-132(63-70-155(223)300)181(326)250-99-164(309)258-134(68-75-166(311)312)190(335)285-153(103-295)210(355)280-147(94-160(228)305)203(348)273-136(66-73-158(226)303)192(337)271-138(69-76-167(313)314)193(338)264-124(48-37-80-243-215(231)232)180(325)249-98-163(308)252-112(17)175(320)261-127(49-38-81-244-216(233)234)183(328)253-113(18)176(321)262-128(50-39-82-245-217(235)236)184(329)260-123(43-25-2)174(230)319/h28-32,44-45,55-62,105-117,123-154,170-173,293-299H,24-27,33-43,46-54,63-104,221-222H2,1-23H3,(H2,223,300)(H2,224,301)(H2,225,302)(H2,226,303)(H2,227,304)(H2,228,305)(H2,229,306)(H2,230,319)(H,249,325)(H,250,326)(H,251,327)(H,252,308)(H,253,328)(H,254,342)(H,255,343)(H,256,352)(H,257,310)(H,258,309)(H,259,307)(H,260,329)(H,261,320)(H,262,321)(H,263,322)(H,264,338)(H,265,330)(H,266,331)(H,267,347)(H,268,353)(H,269,336)(H,270,332)(H,271,337)(H,272,344)(H,273,348)(H,274,357)(H,275,323)(H,276,333)(H,277,334)(H,278,345)(H,279,354)(H,280,355)(H,281,339)(H,282,356)(H,283,358)(H,284,359)(H,285,335)(H,286,340)(H,287,346)(H,288,349)(H,289,341)(H,290,324)(H,291,351)(H,292,350)(H,311,312)(H,313,314)(H,315,316)(H,317,318)(H4,231,232,243)(H4,233,234,244)(H4,235,236,245)(H4,237,238,246)(H4,239,240,247)(H4,241,242,248)/b30-28+/t110-,111-,112-,113-,114-,115-,116-,117+,123-,124-,125-,126-,127+,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,143-,144-,145-,146-,147-,148-,149-,150-,151-,152-,153-,154-,170-,171-,172-,173-/m0/s1</li><li>Key:VQFDKKWXORFBDI-VAVVJCQZSA-N</li><li>Tesamorelin ( INN ; trade name Egrifta SV ) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy , approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans -3-hexenoic acid group. [ 2 ]</li><li># Mechanism of action</li><li>Tesamorelin is the N -terminally modified compound based on 44 amino acids sequence of human GHRH. [ 3 ] This modified synthetic form is more potent and stable than the natural peptide. It is also more resistant to cleavage by the dipeptidyl aminopeptidase than human GHRH. [ 4 ] It stimulates the synthesis and release of endogenous GH, with an increase in level of insulin-like growth factor ( IGF-1 ). The released GH then binds with the receptors present on various body organs and regulates the body composition. This regulation is mainly because of the combination of anabolic and lipolytic mechanisms. However, it has been found that the main mechanisms by which Tesamorelin reduces body fat mass are lipolysis followed by reduction in triglycerides level. [ 5 ]</li><li># Contraindication</li><li>Tesamorelin therapy may cause glucose intolerance and increase the risk of type 2-diabetes, so it is contraindicated in pregnancy. [ 6 ] It is also contraindicated in pregnancy (category X) because it may cause harm to fetus. It is also contraindicated in patients affected by hypothalamic-pituitary axis disruption due to pituitary gland tumor, head irradiation and hypopituitarism . [ 7 ]</li><li># Adverse effects</li><li>Injection site erythema , peripheral edema, injection site pruritus and diarrhea. [ 8 ]</li><li># See also</li><li>List of growth hormone secretagogues</li><li># References</li><li>^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#bf3c2c)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}} "Egrifta (tesamorelin for injection) for Subcutaneous Use. U.S. Full Prescribing Information" (PDF) . EMD Serono, Inc. Archived from the original (PDF) on 18 December 2011 . Retrieved 9 April 2016 .</li><li>^ "FDA Application Chemistry Review" (PDF) . Archived from the original (PDF) on January 2, 2014.</li><li>^ Dhillon S (May 2011). "Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy". Drugs . 71 (8): 1071– 1091. doi : 10.2165/11202240-000000000-00000 . PMID 21668043 . S2CID 195681455 .</li><li>^ Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P (January 2007). "Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue". Basic & Clinical Pharmacology & Toxicology . 100 (1): 49– 58. doi : 10.1111/j.1742-7843.2007.00008.x . PMID 17214611 .</li><li>^ Benedini S, Terruzzi I, Lazzarin A, Luzi L (2008). "Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy". BioDrugs . 22 (2): 101– 112. doi : 10.2165/00063030-200822020-00003 . PMID 18345707 . S2CID 34340539 .</li><li>^ Patel A, Gandhi H, Upaganlawar A (April 2011). "Tesamorelin: A hope for ART-induced lipodystrophy" . Journal of Pharmacy & Bioallied Sciences . 3 (2): 319– 320. doi : 10.4103/0975-7406.80763 . PMC 3103937 . PMID 21687371 .</li><li>^ DeRuiter J, Holston PL. "Review of Selected NMEs 2011" . www.uspharmacist.com . Auburn: Health Information Designs, Inc . Retrieved 2019-06-22 .</li><li>^ Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. (March 2010). "Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension" . Journal of Acquired Immune Deficiency Syndromes . 53 (3): 311– 322. doi : 10.1097/qai.0b013e3181cbdaff . PMID 20101189 . S2CID 13613924 .</li><li>v</li><li>t</li><li>e</li><li>Agonists: Albusomatropin</li><li>Bovine somatotropin</li><li>Efpegsomatropin</li><li>Eftansomatropin alfa</li><li>Growth hormone</li><li>Human placental lactogen</li><li>Lonapegsomatropin</li><li>Placental growth hormone (growth hormone variant)</li><li>Somagrebove</li><li>Somapacitan</li><li>Somatosalm</li><li>Somatotropin</li><li>Somatropin pegol</li><li>Somatrem</li><li>Sometribove</li><li>Somatrogon (MOD-4023; hGH-CTP)</li><li>Somavaratan</li><li>Somavubove</li><li>Somidobove</li><li>Antagonists: G120K-hGH</li><li>Pegvisomant</li><li>Antisense oligonucleotides: Atesidorsen</li><li>Binding proteins: GHBP Tooltip Growth hormone-binding protein</li><li>Agonists: BIM-23052</li><li>CH-275</li><li>Cortistatin-14</li><li>Depreotide</li><li>Edotreotide</li><li>Ilatreotide</li><li>L-803,087</li><li>L-817,818</li><li>Lanreotide</li><li>NNC 26-9100</li><li>Octreotate</li><li>Octreotide</li><li>Pasireotide</li><li>Pentetreotide</li><li>RC-160</li><li>Seglitide</li><li>Somatostatin (GHIH)</li><li>Somatostatin (1-28)</li><li>SRIF-14</li><li>SRIF-28</li><li>TT-232</li><li>Vapreotide</li><li>Veldoreotide</li><li>Antagonists: BIM-23056</li><li>Cyclosomatostatin</li><li>CYN-154806</li><li>Satoreotide</li><li>Agonists: Peptide: ALRN-5281</li><li>CJC-1295</li><li>Dumorelin</li><li>GHRH</li><li>Modified GRF (1-29)</li><li>Rismorelin</li><li>Sermorelin</li><li>Somatorelin</li><li>Tesamorelin</li><li>Antagonists: MZ-5-156</li><li>Agonists: Peptide: Alexamorelin</li><li>EP-51216</li><li>Examorelin (hexarelin)</li><li>Ghrelin</li><li>GHRP-1</li><li>GHRP-3</li><li>GHRP-4</li><li>GHRP-5</li><li>GHRP-6</li><li>Ipamorelin</li><li>Lenomorelin</li><li>Livoletide</li><li>LY-444711</li><li>Pralmorelin (GHRP-2)</li><li>Relamorelin</li><li>Tabimorelin</li><li>Ulimorelin ; Non-peptide: Adenosine</li><li>Anamorelin</li><li>Capromorelin</li><li>CP-464709</li><li>Ibutamoren (MK-677)</li><li>L-692,585</li><li>Macimorelin</li><li>SM-130686 ; Unsorted: LY-426410</li><li>Antagonists: A-778193</li><li>Cortistatin-8</li><li>( D -Lys³)-GHRP-6</li><li>JMV2959</li><li>YIL-781</li><li>See here instead.</li><li>Growth hormone secretagogues</li><li>Growth hormone-releasing hormone receptor agonists</li><li>HIV/AIDS</li><li>Drugs developed by Merck</li><li>Peptides</li><li>Recombinant proteins</li><li>World Anti-Doping Agency prohibited substances</li><li>Articles with short description</li><li>Short description matches Wikidata</li><li>Short description is different from Wikidata</li><li>Drugs with non-standard legal status</li><li>Chemical pages without DrugBank identifier</li><li>Multiple chemicals in Infobox drug</li><li>Chemicals using indexlabels</li><li>Chemical articles with multiple CAS registry numbers</li><li>Articles containing unverified chemical infoboxes</li><li>This page was last edited on 23 December 2025, at 05:20 (UTC) .</li><li>Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc. , a non-profit organization.</li><li>Privacy policy</li><li>Disclaimers</li><li>Contact Wikipedia</li><li>Legal & safety contacts</li><li>Code of Conduct</li><li>Developers</li><li>Statistics</li><li>Cookie statement</li><li>Mobile view</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin" rel="noopener noreferrer" target="_blank">https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin</a></p>
  <ul>
    <li># JavaScript is required...</li><li>Please enable Javascript in order to use PubChem website.</li>
  </ul>
</section>
<section class="peptide-source">
  <h2>Source</h2>
  <p><a href="https://go.drugbank.com/drugs/DB04954" rel="noopener noreferrer" target="_blank">https://go.drugbank.com/drugs/DB04954</a></p>
  <ul>
    <li>Source could not be fetched or parsed.</li>
  </ul>
</section>
            <p class="disclaimer-link"><small>Back to the main peptide list: <a href="../peptides.html">Peptides Overview</a>.</small></p>
          </main>
          <footer>
            © MinMaxMuscle. Discipline builds the body. Systems keep it.
          </footer>
          <script src="../assets/js/script.js"></script>
        </body>
        </html>
